Novartis Ag (NVS) Cash & Equivalents (2009 - 2026)

Novartis Ag has disclosed Cash & Equivalents across 18 years of filings, most recently posting $7.6 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 14.42% year-over-year to $7.6 billion; the TTM figure through Jun 2026 stood at $7.6 billion (up 14.42% YoY), while the FY2025 annual figure was $11.4 billion, changed 0.21% from the prior year.
• Cash & Equivalents came in at $7.6 billion for Q2 2026 at Novartis Ag, up from $6.9 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.9 billion in Q1 2022 to a low of $3.6 billion in Q2 2022.
• Average Cash & Equivalents over 5 years is $9.7 billion, with a median of $9.5 billion recorded in 2024.
• The largest YoY upside for Cash & Equivalents was 264.43% in 2022 against a maximum downside of 39.41% in 2022.
• Over 5 years, Cash & Equivalents stood at $7.5 billion in 2022, then surged by 78.17% to $13.4 billion in 2023, then retreated by 14.44% to $11.5 billion in 2024, then dropped by 0.21% to $11.4 billion in 2025, then tumbled by 33.4% to $7.6 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.6 billion in Q2 2026, $6.9 billion in Q1 2026, and $11.4 billion in Q4 2025.